http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2006501152-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-02 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1709 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-10 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7088 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-15 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-42 |
| filingDate | 2003-05-15^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2006-01-12^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2006501152-A |
| titleOfInvention | Means for use in the treatment of diseases associated with or caused by non-physiological levels of microtubule-bound PP2Ac |
| abstract | The present invention relates to methods for preventing or treating diseases associated with or caused by non-physiologically increased intracellular levels of microtubule-associated protein phosphatase 2A (PP2Ac) catalytic subunit, said method comprising: Administration of a pharmaceutically effective amount of a protein selected from the group of MID1 or MID2 or a nucleic acid encoding the protein to a subject suffering from or at risk of developing the disease. The invention further relates to methods for preventing or treating diseases associated with or caused by non-physiologically reduced intracellular levels of the microtubule-associated protein phosphatase 2A (PP2Ac) catalytic subunit, comprising: To a subject suffering from or at risk of developing the disease, a pharmaceutically effective amount of a peptide fragment of MID1 or MID2, comprising amino acids 108-165 (preferably 110-165) of MID1 or A peptide fragment comprising amino acids 108-165 (preferably 110-165) of MID2, or an effective amount of a fragment of PP2Ac containing a binding site for α4, or a peptide fragment of α4 containing an effective amount of amino acids 236-279 Or an effective amount of the peptide Administration of a nucleic acid molecule encoding a fragment, or an molecule that interferes with an effective amount of MID1 and α4 interaction, or a molecule that interferes with an effective amount of MID1 and / or α4 expression or activity. |
| priorityDate | 2002-05-15^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Showing number of triples: 1 to 550 of 550.